Location
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234
Program Schedule — Mountain Time
10:45 AM – 11:15 AM — Registration and Lunch
11:15 AM – 12:45 PM — Educational Meeting
Meeting Room
Centennial Ballroom DE (Third Floor)
Note, this meeting is in a different room from the other symposia in our series.
Faculty Marianne J Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature
Oncology Service Line, Yale New Haven Health
Oncology Nurse Practitioner-Senior APP II
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
Associate Professor
Yale University School of Nursing
New Haven, Connecticut
Edward B Garon, MD, MS
Professor
Director, Thoracic Oncology Program
Director, Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California
Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology-Baylor Charles A Sammons Cancer Center
Dallas, Texas
Tiffany A Traina, MD, FASCO
Vice Chair, Department of Medicine
Section Head, Triple-Negative Breast Cancer Clinical Research Program
Associate Attending Physician
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Associate Professor
Weill Cornell Medical College
New York, New York
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
10:45 AM – 11:15 AM — Registration and Lunch
11:15 AM – 12:45 PM — Educational Meeting
Rationale for the Use of Antibody-Drug Conjugates (ADCs) as Cancer Treatment
Rationale for conjugating monoclonal antibodies with cytotoxic drugs to form ADCs; theoretical improvement of chemotherapy efficacy while reducing systemic exposure and toxicity
Structural components, such as antibodies, linkers and cytotoxic payloads, of commercially available and investigational ADCs
Direct mechanism of antitumor activity of ADCs and other means by which they can elicit an antitumor effect, such as bystander killing
Current and Future Role of ADCs in Cancer Therapy
FDA-approved indications for ADCs for various tumor types
Promising investigational ADCs in clinical development as anticancer therapy
Setting patient expectations regarding ADC efficacy and tolerability
Optimal timing for initiation of approved ADCs or consideration of a clinical trial evaluating these agents
Cytopenias Associated with ADCs
Educating patients regarding the capacity of ADCs to cause acute chemotherapy-like side effects
Incidence and severity of neutropenia, thrombocytopenia and anemia with approved and investigational ADCs
Indications for prophylactic growth factor use for patients who are about to start treatment with an ADC
Appropriate monitoring of complete blood counts during ADC therapy; thresholds for dose modification, treatment interruption or discontinuation for patients experiencing cytopenias
Gastrointestinal (GI) Adverse Events (AEs) Documented with ADCs
Rates of various GI issues, such as nausea, vomiting, diarrhea, constipation and abdominal pain, in patients receiving ADC therapy
Indications for prophylactic antiemetics and antidiarrheals for patients who are about to start treatment with an ADC
Role of nutritional counseling and diet modifications during ADC treatment
Potential advantages of complementary therapies, such as acupuncture and yoga, for managing GI side effects of ADCs, particularly for patients with anticipatory nausea
Recognition and Management of Interstitial Lung Disease (ILD)/Pneumonitis Associated with ADCs
Pathophysiology of ILD/pneumonitis associated with ADCs; baseline risk factors for its development
Rates, severity and timing of ILD/pneumonitis in clinical trial experiences with various ADCs
Appropriate workup for patients suspected of experiencing therapy-related ILD/pneumonitis; strategies to distinguish drug-related pulmonary toxicity from other potential causes
Guidelines for treatment modifications and discontinuation for patients experiencing ILD/pneumonitis; indications for restarting ADC therapy after side-effect resolution
Utility of other supportive care measures, such as corticosteroids and oxygen supplementation, for patients experiencing ILD/pneumonitis
Cardiovascular AEs with Select ADCs
Pathophysiology of cardiotoxicity associated with anti-HER2 therapies, including ADCs
Incidence of left ventricular dysfunction noted with HER2-targeted ADCs in clinical trial experiences
Appropriate monitoring of left ventricular ejection fraction (LVEF) at baseline and during treatment with HER2-targeted ADCs
Threshold for treatment interruption for patients experiencing LVEF decrease; indications for restarting HER2-targeted ADC therapy after recovery
Role of interdisciplinary coordination with cardiologists in monitoring for and managing cardiac toxicities associated with HER2-targeted ADCs
Potential for Mucositis/Stomatitis with ADCs
Incidence and severity of mucositis/stomatitis with various approved and investigational ADCs
Counseling patients on the importance of oral hygiene during treatment with ADCs known to cause mucositis/stomatitis
Role of prescription steroid mouthwash, homemade mouth rinses, prophylactic antibiotics/antifungals and pain medications for patients who are at risk for or are experiencing mucositis/stomatitis
Dietary recommendations for patients experiencing mucositis/stomatitis
Ocular Toxicities Associated with ADCs
Pathophysiology of ocular AEs associated with certain ADCs; spectrum, incidence and severity of ocular toxicities with different agents
Optimal patient counseling and education regarding signs of ocular toxicity and the importance of early reporting of symptoms
Guidelines for treatment modification for patients experiencing ocular complications of ADCs
Utility of other prophylactic and supportive care measures to mitigate and manage ocular toxicities
Importance of interdisciplinary coordination with eye-care professionals in the identification and management of treatment-related ocular AEs
Other Toxicities Reported with 1 or More ADCs
Incidence and management of peripheral neuropathy associated with various ADCs
Rates of alopecia reported with ADC treatment; available strategies to reduce the incidence and severity of hair loss or limit its psychosocial effects, such as scalp-cooling methods and wigs or hair pieces
Available strategies to ameliorate the symptoms of rash and other cutaneous reactions associated with ADCs
Spectrum of other toxicities, such as fatigue, hemorrhage, effusion/edema and hyperglycemia, associated with 1 or more ADCs
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Consider the scientific justification for the use of antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the targets, structural components and mechanisms of activity of different clinically available and investigational agents in this class.
Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs, and educate patients about to commence therapy with these approaches regarding the potential development of these adverse events and what to do if they are suspected.
Recall strategies commonly employed to identify, manage and mitigate resultant toxicities of anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/ADCs/ILNA.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms Davies has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Garon — Advisory Committees and Consulting Agreements: AbbVie Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Atreca, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, EMD Serono Inc, Gilead Sciences Inc, Hookipa Pharma Inc, I-Mab Biopharma, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Sensei Biotherapeutics, Strata Oncology, Sumitomo Dainippon Pharma Oncology Inc, Summit Therapeutics, Synthekine; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Sponsored Independent Medical Education: Daiichi Sankyo Inc; Travel: A2 Bio, Novartis.
Ms Marti-Smith — Speakers Bureaus: Biotheranostics Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Advantage, Clinical Education Alliance.
Dr Traina — Advisory Committees and Consulting Agreements: Aktis Oncology, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Ellipses Pharma, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Merck, Pfizer Inc, Stemline Therapeutics Inc, TerSera Therapeutics LLC, Veracyte Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room
Centennial Ballroom DE (Third Floor)
Note, this meeting is in a different room from the other symposia in our series.
The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.
There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ONS Congress.
IN-PERSON Registration
Thank you for your interest in our NCPD program taking place in Denver, Colorado. At this time online registration for in-person attendance is closed for this event. LIMITED SEATING IS STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 10:45 AM Mountain Time on Wednesday, April 9th. If you are interested in attending, please visit our registration desk located outside the Centennial Ballroom (Meeting Level 3) at the Hyatt Regency Denver at Colorado Convention Center (650 15thStreet), which is a 5-minute walk to the Colorado Convention Center.
Please note, onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
